Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618461 | 0.92 | KDM5A (0.38) | EPHX1CYP46A1FAAHMGLL | |
| SCHEMBL6103827 | 0.92 | KDM5A (0.38) | EPHX1CYP46A1FAAHMGLL | |
| SCHEMBL1934143 | 0.86 | CD38 (0.39) | HTTCD38 | |
| SCHEMBL4618043 | 0.83 | KMT2A (0.39) | FAAHMGLLEPHX2HTTKMT2A | |
| SCHEMBL6102108 | 0.83 | KMT2A (0.39) | FAAHMGLLEPHX2HTTKMT2A | |
| SCHEMBL1425379 | 0.83 | CD38 (0.43) | EPHX1HTTCD38 | |
| SCHEMBL11878058 | 0.83 | CD38 (0.46) | EPHX1EPHX2HTTCD38 | |
| SCHEMBL10969412 | 0.81 | HTT (0.47) | EPHX1EPHX2HTTCD38 | |
| SCHEMBL4796529 | 0.81 | EPHX1 (0.55) | EPHX1EPHX2HTTKMT2A | |
| SCHEMBL12018143 | 0.80 | EPHX2 (0.44) | CYP46A1EPHX2CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| CN-101472925-B | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | EPHX1 2576/4885CYP46A1 159/4885FAAH 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.